Indexed with PubMed and Science Citation Index (E) 
Users online: 2926 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
    Next article
    Previous article
    Table of Contents

    Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded1    
    Comments [Add]    

Recommend this journal


Year : 1997  |  Volume : 63  |  Issue : 6  |  Page : 354--356

Dexamethasone - Cyclophosphamide pulse (DCP) therapy in Pemphigus

Correspondence Address:
Renu Roy

Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 20944377

Rights and PermissionsRights and Permissions

Of the 37 patients enrolled for this treatment, 13 have been lost to follow up and 4 have died. Of the remaining 20, 8 are already in remission (40%), while 12 are still having active disease. Of the 8 patients who are now in remission, 1 is in phase II and taking monthly dexamethasone cyclophosphamide pulse and 50 mg cyclophosphamide daily while in 3 patients all the treatment has already been withdrawn (phase IV). All these patients are being followed up for any recurrence. The duration of remission has been more than 6 months in 7 patients (maximum 2 years). The chief side-effect observed was increased susceptibility to pyogenic and candidal infections of the skin and oral mucosa respectively. The other side-effects noted were generalized weakness and lethargy following DCP (1), irregular menstrual periods (1), amenorrhoea (1), general darkening of complexion (1), steroid psychosis (1), transient eosinophilia (1) and marked transient oligospermia.

[FULL TEXT] [PDF Not available]*

Print this article     Email this article

Online since 15th March '04
Published by Wolters Kluwer - Medknow